Zitierte eigene Originalien:

• Hinz B, Cheremina O, Brune K (2008) Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 22:383-90
  [Abstract]
  
  
• Hinz B, Cheremina O, Bachmakov J, Renner B, Zolk O, Fromm MF, Brune K (2007) Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans – new insights into the pharmacology of an old analgesic. FASEB J 21:2343-51
  [Abstract]
  
  
• Hinz B, Dormann H, Brune K (2006) More pronounced inhibition of cyclooxygenase-2, increase of blood pressure and decrease of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 54:282-91
  [Abstract]
  
  
• Hinz B, Rau T, Auge D, Werner U, Ramer R, Rietbrock S, Brune K (2003) Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 74:222-35
  [Abstract]
  
  

Weitere Originalien:

• Hinz B, Renner B, Cheremina O, Besz D, Zolk O, Brune K (2009) Lumiracoxib inhibits cyclooxygenase-2 completely at the 50 mg dose: Is liver toxicity avoidable by adequate dosing? Ann Rheum Dis 68:289-91
  [Abstract]
  
  
• Hinz B, Cheremina O, Besz D, Zlotnick S, Brune K (2008) Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. Int J Clin Pharmacol Ther 46:180-6
  [Abstract]
  
  
• Werner U, Lamprecht C, Werner D, Schaefer S, Wuttke H, Hinz B, Fromm MF, Brune K (2006) Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. Int J Clin Pharmacol Ther 44:397-400
  [Abstract]
  
  
• Hinz B, Chevts J, Renner B, Wuttke H, Rau T, Schmidt A, Szelenyi I, Brune K, Werner U (2005) Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol 59:80-4
  [Abstract]
  
  
• Werner U, Werner D, Rau T, Fromm M, Hinz B, Brune K (2003) Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 74:130-7
  [Abstract]
  
  

Ausgewählte Übersichten und Buchbeiträge:

• Hinz B, Brune K (2009) Antipyretic analgesics. In: Bruera E, Portenoy RK (EDS) Cancer Pain: Assessment and management. Cambridge University Press, New York, 255-71
  [Buch-Link]
  
  
• Hinz B, Brune K (2008) Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol Sci 29:391-7
  [Abstract]
  
  
• Brune K, Hinz B (2008) Nonsteroidal anti-inflammatory drugs. In: Walsh D (Ed) Palliative Medicine. 1st Edition. Elsevier, Philadelphia, 740-5
  
  
• Hinz B, Renner B, Brune K (2007) Drug insight: cyclooxygenase-2 inhibitors – a critical appraisal. Nat Clin Pract Rheumatol 3:552-560
  
  
• Hinz B, Brune K (2007) Antipyretic analgesics: Nonsteroidal anti-inflammatory drugs, selective COX-2 inhibitors, paracetamol and pyrazolinones. In: Stein C (Ed) Analgesia. Handbook of Experimental Pharmacology. Vol. 177, Springer-Verlag, Berlin, Heidelberg, 65-94
  
  
• Hinz B, Brune K (2004) Non-steroidal anti-inflammatory drugs – old and new. In: Isenberg DH, Maddison PJ, Woo P, Glass D, Breedveld FC (Eds) Oxford Textbook of Rheumatology. 3rd Edition. Oxford University Press, Oxford, 442-50
  
  
• Hinz B, Brune K (2004) Perspectives and clinical significance of eicosanoids in pain and inflammation. In: Curtis-Prior P (Ed) The eicosanoids. John Wiley & Sons, London, 321-5
  
  
• Hinz B, Brune K (2004) Pain and osteoarthritis: new drugs and mechanisms. Curr Opin Rheumatol 16:628-33
  
  
• Hinz B, Brune K (2002) Cyclooxygenase-2 – Ten years later. J Pharmacol Exp Ther 300:367-75